Global Brand Drugs Market Professional Survey Report 2019

2 Global Brand Drugs Quarterly Market Size Analysis

• 2.1 Brand Drugs Business Impact Assessment - COVID-19
  • 2.1.1 Global Brand Drugs Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
  • 2.1.2 Global Brand Drugs Price, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
• 2.2 Global Brand Drugs Quarterly Market Size 2020-2021
• 2.3 COVID-19-Driven Market Dynamics and Factor Analysis
  • 2.3.1 Drivers
  • 2.3.2 Restraints
  • 2.3.3 Opportunities
  • 2.3.4 Challenges

3 Quarterly Competitive Assessment, 2020

• 3.1 Global Brand Drugs Quarterly Market Size by Manufacturers, 2019 VS 2020
• 3.2 Global Brand Drugs Factory Price by Manufacturers
• 3.3 Location of Key Manufacturers Brand Drugs Manufacturing Factories and Area Served
• 3.4 Date of Key Manufacturers Enter into Brand Drugs Market
• 3.5 Key Manufacturers Brand Drugs Product Offered
• 3.6 Mergers & Acquisitions, Expansion Plans

4 Impact of Covid-19 on Brand Drugs Segments, By Type

• 4.1 Introduction
  • 1.4.1 Biopharmaceutical
  • 1.4.2 Chemistry Medicine
• 4.2 By Type, Global Brand Drugs Market Size, 2019-2021
  • 4.2.1 By Type, Global Brand Drugs Market Size by Type, 2020-2021
  • 4.2.2 By Type, Global Brand Drugs Price, 2020-2021

5 Impact of Covid-19 on Brand Drugs Segments, By Application

• 5.1 Overview
  • 5.5.1 Hospital
  • 5.5.2 Clinic
  • 5.5.3 Other
• 5.2 By Application, Global Brand Drugs Market Size, 2019-2021
  • 5.2.1 By Application, Global Brand Drugs Market Size by Application, 2019-2021
  • 5.2.2 By Application, Global Brand Drugs Price, 2020-2021

6 Geographic Analysis

• 6.1 Introduction
• 6.2 North America
  • 6.2.1 Macroeconomic Indicators of US
  • 6.2.2 US
  • 6.2.3 Canada
• 6.3 Europe
  • 6.3.1 Macroeconomic Indicators of Europe
  • 6.3.2 Germany
  • 6.3.3 France
  • 6.3.4 UK
  • 6.3.5 Italy
• 6.4 Asia-Pacific
  • 6.4.1 Macroeconomic Indicators of Asia-Pacific
  • 6.4.2 China
  • 6.4.3 Japan
  • 6.4.4 South Korea
  • 6.4.5 India
  • 6.4.6 ASEAN
• 6.5 Rest of World
  • 6.5.1 Latin America
  • 6.5.2 Middle East and Africa

7 Company Profiles

• 7.1 Pfizer
  • 7.1.1 Pfizer Business Overview
  • 7.1.2 Pfizer Brand Drugs Quarterly Production and Revenue, 2020
  • 7.1.3 Pfizer Brand Drugs Product Introduction
  • 7.1.4 Pfizer Response to COVID-19 and Related Developments
• 7.2 Roche
  • 7.2.1 Roche Business Overview
  • 7.2.2 Roche Brand Drugs Quarterly Production and Revenue, 2020
  • 7.2.3 Roche Brand Drugs Product Introduction
  • 7.2.4 Roche Response to COVID-19 and Related Developments
• 7.3 Sanofi
  • 7.3.1 Sanofi Business Overview
  • 7.3.2 Sanofi Brand Drugs Quarterly Production and Revenue, 2020
  • 7.3.3 Sanofi Brand Drugs Product Introduction
  • 7.3.4 Sanofi Response to COVID-19 and Related Developments
• 7.4 Johnson & Johnson
  • 7.4.1 Johnson & Johnson Business Overview
  • 7.4.2 Johnson & Johnson Brand Drugs Quarterly Production and Revenue, 2020
  • 7.4.3 Johnson & Johnson Brand Drugs Product Introduction
  • 7.4.4 Johnson & Johnson Response to COVID-19 and Related Developments
• 7.5 Merck & Co. (MSD)
  • 7.5.1 Merck & Co. (MSD) Business Overview
  • 7.5.2 Merck & Co. (MSD) Brand Drugs Quarterly Production and Revenue, 2020
  • 7.5.3 Merck & Co. (MSD) Brand Drugs Product Introduction
  • 7.5.4 Merck & Co. (MSD) Response to COVID-19 and Related Developments
• 7.6 Novartis
  • 7.6.1 Novartis Business Overview
  • 7.6.2 Novartis Brand Drugs Quarterly Production and Revenue, 2020
  • 7.6.3 Novartis Brand Drugs Product Introduction
  • 7.6.4 Novartis Response to COVID-19 and Related Developments
• 7.7 AbbVie
  • 7.7.1 AbbVie Business Overview
  • 7.7.2 AbbVie Brand Drugs Quarterly Production and Revenue, 2020
  • 7.7.3 AbbVie Brand Drugs Product Introduction
  • 7.7.4 AbbVie Response to COVID-19 and Related Developments
• 7.8 Gilead Sciences
  • 7.8.1 Gilead Sciences Business Overview
  • 7.8.2 Gilead Sciences Brand Drugs Quarterly Production and Revenue, 2020
  • 7.8.3 Gilead Sciences Brand Drugs Product Introduction
  • 7.8.4 Gilead Sciences Response to COVID-19 and Related Developments
• 7.9 GlaxoSmithKline (GSK)
  • 7.9.1 GlaxoSmithKline (GSK) Business Overview
  • 7.9.2 GlaxoSmithKline (GSK) Brand Drugs Quarterly Production and Revenue, 2020
  • 7.9.3 GlaxoSmithKline (GSK) Brand Drugs Product Introduction
  • 7.9.4 GlaxoSmithKline (GSK) Response to COVID-19 and Related Developments
• 7.10 Amgen
  • 7.10.1 Amgen Business Overview
  • 7.10.2 Amgen Brand Drugs Quarterly Production and Revenue, 2020
  • 7.10.3 Amgen Brand Drugs Product Introduction
  • 7.10.4 Amgen Response to COVID-19 and Related Developments
• 7.11 AstraZeneca
  • 7.11.1 AstraZeneca Business Overview
  • 7.11.2 AstraZeneca Brand Drugs Quarterly Production and Revenue, 2020
  • 7.11.3 AstraZeneca Brand Drugs Product Introduction
  • 7.11.4 AstraZeneca Response to COVID-19 and Related Developments
• 7.12 Bristol-Myers Squibb
  • 7.12.1 Bristol-Myers Squibb Business Overview
  • 7.12.2 Bristol-Myers Squibb Brand Drugs Quarterly Production and Revenue, 2020
  • 7.12.3 Bristol-Myers Squibb Brand Drugs Product Introduction
  • 7.12.4 Bristol-Myers Squibb Response to COVID-19 and Related Developments
• 7.13 Eli Lilly
  • 7.13.1 Eli Lilly Business Overview
  • 7.13.2 Eli Lilly Brand Drugs Quarterly Production and Revenue, 2020
  • 7.13.3 Eli Lilly Brand Drugs Product Introduction
  • 7.13.4 Eli Lilly Response to COVID-19 and Related Developments
• 7.14 Teva
  • 7.14.1 Teva Business Overview
  • 7.14.2 Teva Brand Drugs Quarterly Production and Revenue, 2020
  • 7.14.3 Teva Brand Drugs Product Introduction
  • 7.14.4 Teva Response to COVID-19 and Related Developments
• 7.15 Bayer
  • 7.15.1 Bayer Business Overview
  • 7.15.2 Bayer Brand Drugs Quarterly Production and Revenue, 2020
  • 7.15.3 Bayer Brand Drugs Product Introduction
  • 7.15.4 Bayer Response to COVID-19 and Related Developments
• 7.16 Novo Nordisk
  • 7.16.1 Novo Nordisk Business Overview
  • 7.16.2 Novo Nordisk Brand Drugs Quarterly Production and Revenue, 2020
  • 7.16.3 Novo Nordisk Brand Drugs Product Introduction
  • 7.16.4 Novo Nordisk Response to COVID-19 and Related Developments
• 7.17 Allergan
  • 7.17.1 Allergan Business Overview
  • 7.17.2 Allergan Brand Drugs Quarterly Production and Revenue, 2020
  • 7.17.3 Allergan Brand Drugs Product Introduction
  • 7.17.4 Allergan Response to COVID-19 and Related Developments
• 7.18 Takeda
  • 7.18.1 Takeda Business Overview
  • 7.18.2 Takeda Brand Drugs Quarterly Production and Revenue, 2020
  • 7.18.3 Takeda Brand Drugs Product Introduction
  • 7.18.4 Takeda Response to COVID-19 and Related Developments
• 7.19 Boehringer Ingelheim
  • 7.19.1 Boehringer Ingelheim Business Overview
  • 7.19.2 Boehringer Ingelheim Brand Drugs Quarterly Production and Revenue, 2020
  • 7.19.3 Boehringer Ingelheim Brand Drugs Product Introduction
  • 7.19.4 Boehringer Ingelheim Response to COVID-19 and Related Developments
• 7.20 Takeda
  • 7.20.1 Takeda Business Overview
  • 7.20.2 Takeda Brand Drugs Quarterly Production and Revenue, 2020
  • 7.20.3 Takeda Brand Drugs Product Introduction
  • 7.20.4 Takeda Response to COVID-19 and Related Developments

8 Supply Chain and Sales Channels Analysis

• 8.1 Brand Drugs Supply Chain Analysis
  • 8.1.1 Brand Drugs Supply Chain Analysis
  • 8.1.2 Covid-19 Impact on Brand Drugs Supply Chain
• 8.2 Distribution Channels Analysis
  • 8.2.1 Brand Drugs Distribution Channels
  • 8.2.2 Covid-19 Impact on Brand Drugs Distribution Channels
  • 8.2.3 Brand Drugs Distributors
• 8.3 Brand Drugs Customers

9 Key Findings

10 Appendix

• 10.1 About Us